Caribou Biosciences News and Activities

Caribou Biosciences is a company listed under the stock ticker CRBU (US).

View the org chart displaying its 25 main executives

Most searched biographies at Caribou Biosciences

• Rachel Haurwitz, Director, President and Chief Executive Officer
• Natalie Sacks, Director
• Dara Richardson-Heron, Director

Popular executive movements at Caribou Biosciences

• Denis Sirringhaus has joined the company as Vice President of Business Development  (posted on December 22 2025).

Create your alert
to follow the executive moves at Caribou Biosciences.

Caribou Biosciences has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Caribou Biosciences

• Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference | Caribou Biosciences, Inc.
• Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference | Caribou Biosciences, Inc.
• Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting | Caribou Biosciences, Inc.
• Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference | Caribou Biosciences, Inc.
• Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update | Caribou Biosciences, Inc.
• Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy | Caribou Biosciences, Inc.
• Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Caribou Biosciences, Inc.
• Caribou Biosciences to Participate in Upcoming Investor Conferences | Caribou Biosciences, Inc.
• Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR® | Caribou Biosciences, Inc.
• Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025 | Caribou Biosciences, Inc.
• View more press releases Close

Social media about Caribou Biosciences

• Caribou Biosciences on Wikipedia, Google News & Yahoo Finance
• Caribou Biosciences on LinkedIn, X (Twitter) & YouTube